INTRODUCTION
Atopic dermatitis (AD) is a chronic, inflammatory skin disease clinically characterized by eczematous lesions and severe itch, significantly affecting the patients' quality of life. AD is classified as mild, moderate, or severe according to the extent and severity of these lesions. While therapeutic protoc...
A. Costanzo, A. Campanati, M. Esposito et al.· Dermatologic Therapy· 0 citations
INTRODUCTION
Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control.
METHODS
This multicenter retrospective analysis of prospectively collected LANDSC...
L. Potestio, M. Bianco, L. Mastorino et al.· Dermatologic Therapy· 0 citations
BACKGROUND
Atopic dermatitis (AD) in the elderly is increasing worldwide and presents therapeutic challenges due to age-related comorbidities that often contraindicate systemic therapies. Although oral Janus kinase (JAK) inhibitors show efficacy in moderate-to-severe AD, older adult patients are underrepresented in cli...
E. Ippoliti, N. Gori, G. Coscarella et al.· Dermatitis· 0 citations
Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 weeks in routine...
L. Potestio, S. Corrao, L. Mastorino et al.· Dermatologic Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
